Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial-Reference-Cited by-同舟云学术

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Published:2023-04 Issue:4 Volume:11 Page:233-241
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Schechter Meir,Wiviott Stephen D,Raz Itamar,Goodrich Erica L,Rozenberg Aliza,Yanuv Ilan,Murphy Sabina A,Zelniker Thomas A,Fredriksson Martin,Johansson Peter A,Leiter Lawrence A,Bhatt Deepak L,McGuire Darren K,Wilding John P H,Gause-Nilsson Ingrid A M,Cahn Avivit,Langkilde Anna Maria,Sabatine Marc S,Mosenzon Ofri

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference27 articles.

1. Factors contributing to increases in diabetes-related preventable hospitalization costs among U.S. adults during 2001–2014;Shrestha;Diabetes Care,2019

2. Economic costs of diabetes in the U.S. in 2017;Diabetes Care,2018

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of dapagliflozin on readmission and loop diuretics use in patients with acute heart failure: a retrospective propensity score-matched cohort study;BMC Cardiovascular Disorders;2024-08-02

2. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial;Diabetes Research and Clinical Practice;2024-06

3. Update Typ-2-Diabetes;Die Diabetologie;2024-05-22

4. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10

5. SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors;Clinical Pharmacology & Therapeutics;2024-02-09